Nachrichten zur Moderna Inc. Aktie

US FDA to initiate review of Modernas influenza vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.…

Moderna’s investigational flu vaccine moves forward in FDA review

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal…

Moderna Aktie: Showdown im März und Phase-3-Daten im Anflug!

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Morgan Stanley:Die Analysten von Morgan Stanley haben das Votum für die Aktie von Moderna…

Moderna erhöht Cash-Polster - Sinkende US-COVID-Erlöse

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse von BofA Securities:Die Analysten von BofA Securities haben das Kursziel für Moderna Inc. (ISIN: US60770K1079, WKN:…

Moderna: Umsatz-Überraschung und Krebs-Pipeline – der Startschuss für die Neubewertung ist gefallen!

Moderna trotzt dem Abgesang auf die Post-Covid-Ära und übertrifft mit einem Umsatz von 678 Mio. USD im 4. Quartal die…

Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus

…

Stocks making the biggest moves midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & more

Here are some of the biggest movers in midday trading.…

Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates

MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and…

ROUNDUP/Nach Umsatzeinbruch: Moderna will 2026 wieder wachsen

CAMBRIDGE (dpa-AFX) - Ungeachtet eines überraschend starken Schlussquartals hat der US-Pharmakonzern Moderna 2025 einen harschen…

Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic...

…

Nach Umsatzeinbruch: Moderna will 2026 wieder wachsen

CAMBRIDGE (dpa-AFX) - Ungeachtet eines überraschend starken Schlussquartals hat der US-Pharmakonzern Moderna 2025 einen harschen…

Earnings Snapshot: Moderna tops Q4; sees up to 10% revenue growth, lower expenses in 2026

…

Moderna beats quarterly revenue estimates on resilient sales of COVID shot

Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the…

Moderna shares pop on strong guidance, smaller-than-expected loss

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11%…

HHS Casts Doubts On mRNA Products, But Funds Studies On Debunked Theories

Its conspicuous that HHS refuses to review Modernas application for regulatory approval of an mRNA-based flu vaccine while it prioritizes…

Moderna: Stock to Avoid or Bad News Buy?

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.…

Moderna Aktie: Regulatorischer Dämpfer - Grippeimpfstoff mRNA-1010 im Fokus

Boston, MA (www.aktiencheck.de) - Moderna-Aktienanalyse von Leerink Partners:Die Analysten von Leerink Partners stufen die Aktie von Moderna Inc. (ISIN: US60770K1079,…

Moderna Aktie: FDA stoppt Grippeimpfstoff-Antrag, Break-even rutscht auf 2030

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse der Bank of America (BofA):BofA habe das Kursziel für die Aktie von Moderna Inc. (ISIN: US60770K1079,…

Modernas investigational flu vaccine denied FDA review, shares drop

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares fell almost 6% after the drugmaker announced that the US Food and Drug Administration’s (FDA) Center…

Stocks making the biggest moves premarket: Lyft, Moderna, Cloudflare, Ford, Zillow Group and more

These are the stocks posting the largest moves in early trading.…

FDA refuses to review Moderna’s influenza vaccine application By Reuters

FDA refuses to review Moderna’s influenza vaccine application…

Moderna says FDA refuses to review its application for experimental flu shot

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.…

Moderna to supply respiratory vaccines to Mexico as part of five-year deal

…

Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Moderna faces $5 billion mRNA patent lawsuit after Star Trek ruling

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026,…

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior days close.…

Moderna Aktie: Rückenwind für Biotech

London (www.aktiencheck.de) - Moderna-Aktienanalyse von Barclays:Barclays-Analystin Eliana Merle habe die Coverage der Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9,…

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Moderna (MRNA) closed the most recent trading day at $47.99, moving 1.48% from the previous trading session.…

Moderna chief: Company won’t invest in new late-stage vaccine trials

Moderna has already been facing declines in sales after a boom during the COVID-19 pandemic.…

Stocks making the biggest moves midday: Fortinet, Moderna, Intel, Bausch Health & more

These are the stocks posting the largest moves in midday trading.…

Moderna stock surges for fourth consecutive day, hitting 2024 high By Investing.com

Moderna stock surges for fourth consecutive day, hitting 2024 high…

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV By Reuters

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV…

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials,…

Mehr als nur Covid: Wie Moderna mit KI und mRNA den Krebs besiegen will

Trotz aktueller operativer Verluste sichert das Unternehmen seine Zukunft durch ein massives Cash-Polster von über 8 Mrd. USD ab…

Moderna: Das lange Warten auf den Krebs-Durchbruch könnte bald ein Ende haben

Wir schreiben Januar 2026, und ein Blick auf den Aktienkurs von Moderna zeigt, dass der "Long Covid"-Effekt an der Börse…

Why Moderna Stock Surged Today

The vaccine maker is expanding beyond its COVID-focused offerings.…

Moderna (MRNA) Increases Despite Market Slip: Heres What You Need to Know

Moderna (MRNA) closed at $43 in the latest trading session, marking a +2.8% move from the prior day.…

Moderna (MRNA) Increases Despite Market Slip: Heres What You Need to Know

Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.…

Warum der Einstieg bei Moderna meines Erachtens zum jetzigen Zeitpunkt eine vielversprechende Chance darstellt!

Die Aktie von Moderna befindet sich in einem mehrjährigen Abwärtstrend und könnte nun eine Bodenbildung vollziehen, nachdem das Unternehmen am…

Health Care Roundup: Market Talk

Find insight on Merck & Co., Moderna and more in the latest Market Talks covering Health Care.…

Stocks making the biggest moves midday: JPMorgan, Moderna, Boeing, Cardinal Health, Chipotle & more

These are some of the stocks posting the largest midday moves.…

Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story

…

Market movers: Synchrony Financial, Capital One, NextSource Materials, Moderna...

…

Moderna expects 2025 revenue of $1.9B, above guidance

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of…

Moderna stock rises as revenue outlook exceeds estimates By Investing.com

Moderna stock rises as revenue outlook exceeds estimates…

Moderna expects $1.9 billion in sales, trims costs forecast for 2025

Moderna said on Monday it expects to report around $1.9 ?billion in sales for 2025, putting it near the upper…

Moderna (MRNA) Stock Sinks As Market Gains: Heres Why

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.…

Moderna Aktie: Kursziel rauf - doch BofA sieht weiter Abwärtsrisiken

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse von BofA Securities:Tim Anderson, Analyst von BofA Securities, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079,…

Moderna just had its best day since October. Heres whats going on, and what analysts expect

Analysts pointed to an upcoming health care conference and cancer data study release as potential catalysts for Modernas ongoing rally.…

Moderna Aktie: Warum die Umsatzhoffnung jetzt wackelt

Zürich (www.aktiencheck.de) - Moderna-Aktienanalyse der UBS:UBS habe die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA)…